High-concentration biologics are reshaping formulation, manufacturing, and delivery strategies to address challenges related to viscosity and stability in subcutaneous (SC) administration. Drug concentrations exceeding 100 mg/mL are classified as high dose, while those at or above 250 mg/mL are deemed ultra-high dose, typically requiring injection volumes around 2 mL. The complexity of these formulations arises from issues such as aggregation and long-term stability, which are critical for effective treatment of serious conditions like rheumatoid arthritis and neurological disorders.
Currently, approximately 46 high-concentration antibodies are marketed, with 34 approved for SC administration. However, the pain associated with SC injections remains a significant concern. Studies indicate that injection volumes exceeding 1.5 mL can increase discomfort, prompting research into optimal viscosity levels to enhance patient tolerance. Innovations in formulation techniques, including the use of viscosity-reducing agents and advanced delivery devices, are essential to facilitate the safe and effective administration of these high-dose biologics.
Start your 7-day trial and see what the database can do →
